NCT00993915已完成不适用
Non Interventional (NI) Open Label Prospective Study On Liprimar (Atorvastatin) In Patients With Coronary Heart Disease (CHD) And High Risk Of Cardiovascular Complications
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.0 个研究点目标入组 687 人开始时间: 2010年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 687
- 主要终点
- Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit
研究概览
简要总结
In which CHD patients with high risk of CV complications are different doses of LIPRIMAR used? For this purpose, data on hyperlipidemia will be elicited over and above the basic nosographic and demographic data, concomitant diseases and cardiovascular risk factor.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients, who eligible to sign informed consent;
- •Patients with indications to lipid lowing therapy, according to local product document.
- •Patients with CHD and high risk of CV complications (Diabetes Mellitus II, Myocardial Infarction, Heart Failure, Arterial Hypertension, ets) will be included into study;
- •Patients with LDL levels: > 3,5 mmol/l
排除标准
- •Individual intolerance of atorvastatin, in accordance to local product document.
研究组 & 干预措施
Main group
Newly diagnosed or known coronary artery disease and known dislipidemia and high risk of cardiovascular complications
干预措施: Atorvastatin (Drug)
结局指标
主要结局
Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit
时间窗: Month 6
次要结局
- Percentage of Participants Achieving LDL Level ≤ 100 mg/dL at the 1 Month Visit(Month 1)
- Change From Baseline in Lipid Parameters(Month 6)
- Percent Change From Baseline in Lipid Parameters(Month 6)
研究者
相似试验
招募中
不适用
Cardiovascular Risk Factors , Complications and Threputic Management Strategies in Patients With Coronary Heart Disease and COVID 19Ischemic Heart DiseaseNCT05092711Assiut University150
已完成
3 期
Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive AdultsHIV InfectionsNCT00389207Boehringer Ingelheim576
已完成
不适用
Effects of Nutraceutical Therapies on Endothelial Function, Platelet Aggregation, and Coronary Flow ReserveEndothelial DysfunctionHypercholesterolemiaNCT02969070Federico II University28
已完成
2 期
Study of A Combination Pill With GS-7977 and GS-5885 for Hepatitis C in People With HIVHIVHepatitis CNCT01878799National Institute of Allergy and Infectious Diseases (NIAID)50
已完成
2 期
A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.Hepatitis C, ChronicNCT00377182Hoffmann-La Roche107